← Medtronic overview

Medtronic vs Boston Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Medtronic PLC (MDT)

Q3 2026
▲6▼3

Medtronic gains on reimbursement, acquisitions, AI launches; risks persist

  • Renal denervation reimbursement win Medtronic secured permanent reimbursement codes for its renal denervation therapy, a key step to commercial adoption. This should drive sales growth and strengthen its position in hypertension treatment.

    This is a new regulatory and commercial milestone that directly supports future revenue.

  • SPR Therapeutics acquisition completed Medtronic completed the acquisition of SPR Therapeutics, adding a peripheral nerve stimulation platform. This expands its pain management portfolio and offers a new growth avenue.

    This is a new acquisition that broadens Medtronic's product offerings and potential revenue.

  • AI-native surgical platform launched Medtronic launched an AI-native surgical platform with FDA clearance, aiming to enhance surgical outcomes. This innovation could differentiate its offerings and drive adoption.

    This is a new product launch that showcases Medtronic's technological advancement.

  • LigaSure cleared for Hugo robot FDA clearance for LigaSure on the Hugo robot expands the robot's capabilities. This strengthens Medtronic's competitive position in robotic surgery against Intuitive Surgical.

    This is a new regulatory clearance that enhances the Hugo robot's functionality.

  • UBS upgrade and strong revenue growth UBS upgraded Medtronic stock, citing improving fundamentals. Revenue grew 8.4%, a decade high, and guidance was raised, reflecting strong business momentum.

    This is a new analyst upgrade and financial performance update that boosts investor confidence.

  • MiniMed diabetes spin-off advances Medtronic advanced the spin-off of its MiniMed diabetes business, a strategic move to unlock value. This could streamline operations and focus on core medtech.

    This is a new corporate action that may enhance shareholder value.

  • Octopus 4 recall and Bravo CF alert A Class II recall for Octopus 4 devices and an FDA alert linking 184 injuries to Bravo CF devices raise safety concerns. These may lead to regulatory scrutiny and reputational damage.

    These are new negative regulatory events that could impact sales and trust.

  • Hernia mesh verdict and lawsuits An $88 million hernia mesh verdict and over 2,400 pending lawsuits create legal overhang. This poses financial risk and distracts management.

    This is a new legal development with potential financial impact.

  • Tariffs and competitive pressures Medtronic faces $250 million in annual tariffs and competitive pressure from Abbott and J&J. Physician caution in cardiovascular procedures adds uncertainty.

    These are ongoing external challenges that could weigh on margins and growth.

August 2026
▲2▼2

Medtronic gains on strong earnings, upgrade, and pipeline expansion

  • UBS upgrade and decade-high revenue growth UBS upgraded Medtronic to Buy, and revenue grew 8.4%, the fastest in a decade, driven by an 88% jump in Cardiac Ablation Solutions. Q1 beat estimates, leading to raised full-year guidance.

    This point captures the main positive drivers that boosted investor confidence and the stock price.

  • Pipeline expansion through acquisitions and partnerships Medtronic expanded its pipeline with acquisitions, a $700 million robotics partnership, and approvals for the Affera system, strengthening its position in key markets and supporting future growth.

    This point highlights strategic moves that contribute to long-term growth potential.

  • Tariffs, legal verdict, and FDA alert create headwinds Medtronic faces $250 million in annual tariffs, an $88 million hernia mesh verdict with over 2,400 lawsuits pending, and an FDA alert linking 184 injuries to Bravo CF devices, adding legal and cost pressures.

    This point outlines the significant risks that could weigh on the stock and investor sentiment.

  • Competitive pressure and physician caution Competition from Abbott and Johnson & Johnson, along with physician caution in cardiovascular procedures, poses ongoing challenges that could limit Medtronic's market share and growth.

    This point addresses external competitive and behavioral factors that may hinder performance.

Latest
▲3

Medtronic Beats, Raises Guidance, Expands Robotics and Ablation

  • Q1 beat and raised guidance Medtronic reported 13.7% revenue growth to $9.76 billion and raised full-year guidance, with adjusted EPS up 15.1%. An extra week added $570 million, so growth won't repeat at that pace, but the beat and higher outlook support the stock.

    This is the biggest new financial event, directly driving investor confidence and the stock's valuation.

  • Cardiac Ablation Solutions tops $2B Medtronic's Cardiac Ablation Solutions unit surpassed $2 billion in trailing 12-month revenue, ahead of its target, helped by new approvals for the Affera system in Europe and Canada. This shows its bet on heart-rhythm devices is paying off.

    It highlights a key growth driver and validates Medtronic's competitive position in a fast-growing market.

  • $700M robotics deal expands offerings Medtronic signed a $700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system globally, adding a second robotics platform alongside its Hugo system. This broadens its menu for hospitals and could boost procedure volumes over time.

    It is a major new strategic investment that expands Medtronic's robotics presence and future revenue potential.

  • Legal and regulatory setbacks Medtronic faced an $88 million hernia mesh verdict and an FDA early alert for its Bravo CF delivery devices after 184 injuries. These are negative for sentiment and could lead to costs, but they are smaller than the positive growth drivers.

    It provides a fair counterweight, showing real risks that could pressure the stock despite strong results.

September 2026
▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

▲3▼1

Medtronic beats Q1, raises guidance on heart device strength

  • Q1 beat and raised guidance Medtronic reported fiscal Q1 revenue of $9.8 billion, up 13.7%, and adjusted EPS of $1.45, beating estimates. It raised full-year organic growth guidance to 7.25%-7.75% and EPS to $5.94-$6.00. This shows the business is growing faster than expected, which lifts the stock.

    This is the main new event that directly moves MDT's price.

  • Cardiac Ablation Solutions surge Cardiac Ablation Solutions grew 88% worldwide, and Cardiac Rhythm Management rose 15%. These heart-related products are driving most of the growth. Continued strength here supports the stock because it shows Medtronic is winning in a key market.

    It explains the underlying driver of the strong quarter and future growth.

  • Strategic deals and partnerships Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics, announced a partnership with Cornerstone Robotics, and invested in Pi-Cardia. These moves expand its product pipeline and technology, which can support future growth and investor confidence.

    New deals signal long-term growth potential beyond the current quarter.

  • Tariff costs and competition Medtronic expects $250 million in annual tariff costs, with $75 million hitting Q1. Also, Abbott's new diabetes device adds competition. These are real headwinds that could pressure profits and limit upside, even as the core business grows.

    It provides a fair counterweight to the positive earnings news.

▼3▲1

Medtronic's strong growth and UBS upgrade offset by tariff and legal headwinds

  • UBS upgrade and strong revenue growth UBS upgraded Medtronic to Buy, citing a turnaround. The company reported its highest annual revenue growth in a decade, with fiscal 2026 revenue up 8.4% to $36.4 billion, driven by a 78% surge in Cardiac Ablation Solutions. This positive momentum could attract more investors and push the stock higher.

    This is a new positive development that directly boosts investor confidence and the stock's outlook.

  • Tariff headwinds Medtronic absorbed a $74 million tariff impact in the latest quarter and expects roughly $250 million in fiscal 2027. These tariffs increase costs and could pressure profit margins, potentially weighing on the stock price.

    This is a new negative factor that affects future profitability and is a key concern for investors.

  • Hernia mesh lawsuit verdict A federal jury ordered Medtronic to pay $88 million in the first Covidien hernia mesh bellwether trial, with over 2,400 similar lawsuits pending. This creates legal uncertainty and potential financial liability, which could negatively impact the stock.

    This is a new legal development that introduces significant risk and could lead to further payouts.

  • Competitive pressure in cardiovascular Johnson & Johnson's MedTech cardiovascular segment grew only 3.1%, and Abiomed declined 2% amid physician caution. This suggests a challenging environment for Medtronic's cardiovascular business, potentially limiting growth.

    This is a new competitive signal that highlights potential headwinds for Medtronic's cardiovascular sales.

July 2026
▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

Q2 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

June 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

Boston Scientific Corp (BSX)

Q3 2026
▼4

Boston Scientific's 2026 Q3: cyberattack, recalls, and guidance cuts overshadow deals

  • August cyberattack hits sales and guidance An August cyberattack cost roughly $300 million in Q3 sales and $0.13 per share, forcing Boston Scientific to cut its guidance again. This was a major new setback that hurt investor confidence.

    This was a major new negative event that directly reduced sales and earnings and caused a guidance cut.

  • Multiple recalls raise regulatory and reputational risk Several product recalls, including a serious Class I ENROUTE recall, increased regulatory and reputational risk. These issues can lead to fines, sales losses, and damage to the company's reputation.

    Recalls are new negative events that add regulatory and reputational pressure on the stock.

  • EP growth stalls and key launches delayed Electrophysiology growth stalled and key product launches were delayed to 2027–28. This raised doubts about future revenue growth and competitive position.

    Stalled growth and delayed launches are new negative developments that threaten future earnings.

  • Citi downgrade on rising competition Citi downgraded Boston Scientific, citing rising competition and expected 2027 share loss to Abbott's Amulet. This analyst action reflected and reinforced negative sentiment.

    The downgrade is a new negative event that directly weighs on investor sentiment and the stock price.

August 2026
▼3▲1

Cyberattack, recalls and stalled EP growth hit BSX; new products and defense deal offer hope

  • Cyberattack disrupts orders and shipments A cyberattack disrupted orders and shipments, costing an estimated $300 million in third-quarter sales and $0.13 per share, with the full damage unclear until October 28. This directly hit near-term revenue and profit.

    This is the biggest new negative event of the period and directly explains the price pressure.

  • Class I ENROUTE recall and other recalls add pressure Multiple recalls, including a Class I ENROUTE recall, added regulatory and reputational pressure. Class I is the most serious FDA category, meaning the device may cause serious harm or death.

    This is a new escalation of previously reported recall issues and adds regulatory risk.

  • Electrophysiology growth stalls; key launches delayed Electrophysiology growth stalled, with key launches (FARAWAVE Ultra, FARAFLEX) delayed to 2027–28. This pushes out expected new revenue and keeps the company behind competitors in a key heart-rhythm market.

    This is a new setback for a major growth area and explains why investors remain cautious.

  • New products and defense contract offer future growth BSX is preparing new products (SEISMIQ 4CE, RIVOS, PRECEDENT) and won a defense contract worth up to $135.7 million. These are positive steps, but most benefits will only show up from 2027 onward.

    This is the main new positive counterweight to the negative events of the period.

Latest
▼2▲1

BSX: cyberattack cost, weak EP, new launches and a leadership reset

  • Cyberattack cost now quantified Wells Fargo estimates the August cyberattack cost about $300 million in third-quarter sales and $0.13 per share, cutting its target to $48. Shipping is restored, but the full damage is still unknown until the October 28 update, so the stock stays under pressure.

    This is the main new, concrete number behind BSX's weakness and the key uncertainty still hanging over the stock.

  • Electrophysiology growth stalls, launches pushed to 2027-28 BSX says global electrophysiology growth will be flat in the second half of 2026 because of competition and gaps in its heart-rhythm portfolio. The next big product launches, including FARAWAVE Ultra and FARAFLEX, only arrive in 2027-2028, delaying the recovery.

    It explains why a core growth engine is stalling and why the payoff from new products is still years away.

  • Product launch wave and defense contract support future growth BSX is lining up launches like the SEISMIQ 4CE catheter, FDA-cleared RIVOS and the PRECEDENT defibrillator, and won a defense health contract worth up to $135.7 million for heart procedure supplies. These add future revenue, though most benefit lands in 2027 and beyond.

    It shows the concrete new sources of growth that could offset the current weak spots.

  • Leadership reset and recall add execution risk BSX named Joseph Fitzgerald as COO and split into three segments, targeting about $500 million in annual savings by 2029, while a voluntary recall of 982 StoneSmart consoles and the retirement of a key MedSurg executive add near-term disruption. The reorganization is a bet whose payoff is only visible in 2027.

    It captures the new management and quality issues that could help or hurt depending on execution.

September 2026
▼3▲1

Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh

  • Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.

    This is the main new negative event that directly caused the guidance cut and stock drop.

  • Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.

    This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.

  • Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.

    This is a major new strategic move that offsets some negative sentiment and shows future growth potential.

  • Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.

    This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.

▼3▲1

Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh

  • Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.

    This is the main new negative event that directly caused the guidance cut and stock drop.

  • Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.

    This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.

  • Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.

    This is a major new strategic move that offsets some negative sentiment and shows future growth potential.

  • Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.

    This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.

▼2

BSX hit by cyberattack and recalls as growth outlook weakens

  • Cybersecurity incident disrupts orders and shipments BSX disclosed a cyberattack that disrupted IT systems worldwide, hurting its ability to process and ship customer orders. The stock fell as much as 5.9% in one day. The financial cost is still unknown, so investors face uncertainty about lost sales and cleanup expenses.

    This is the biggest new event of the period and directly explains the sharp price drop.

  • New worldwide recalls add regulatory and reputational pressure BSX issued multiple recalls, including a serious Class I recall of its ENROUTE neuroprotection system and Class II recalls of OverStitch devices. These affect high-risk procedures and could disrupt hospital ordering. Recalls raise costs, invite regulatory scrutiny, and can damage trust with doctors and patients.

    This is a fresh negative event that adds to the company's operational and reputational problems.

July 2026
▲2▼2

BSX beat Q2 but cut guidance twice on WATCHMAN and EP share losses

  • Guidance cut twice on WATCHMAN weakness and lost EP share Boston Scientific lowered its 2026 outlook twice, blaming weak demand for its WATCHMAN heart implant and lost U.S. electrophysiology market share. This directly hurt investor confidence and near-term profit expectations.

    The repeated guidance cuts are the main negative force on the stock this period.

  • Q2 beat and $500M restructuring savings plan The company beat second-quarter estimates and launched a restructuring aimed at saving $500 million a year by 2029. Cost cuts can protect profits while sales growth is slow.

    This is a new positive offset to the weak demand and share-loss news.

  • $1.5B MiRus stake and $3B TAVR option Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an exclusive $3 billion option to buy a TAVR heart-valve business. This expands its cardiology pipeline for future growth.

    A major new capital deployment that supports the longer-term growth story.

  • Multiple recalls raise safety and regulatory concerns Recalls hit CRE endoscopy devices, ENROUTE catheters (FDA warning after tip separation), FARADRIVE ablation generators, vascular sheaths, and Orca valves. These quality problems add regulatory and reputational risk.

    The wave of recalls is a new negative that weighs on trust and future sales.

▼3▲1

BSX cuts 2026 outlook on WATCHMAN and EP weakness; recalls add pressure

  • 2026 guidance cut on WATCHMAN and electrophysiology weakness Boston Scientific lowered its 2026 sales growth and earnings guidance, citing weaker WATCHMAN heart-implant demand and lost U.S. electrophysiology market share. This directly reduces expected future profits, pushing the stock down as investors reprice slower growth.

    This is the core new event that answers why BSX is moving now.

  • New recalls of cardiac ablation generators and vascular sheaths Boston Scientific recalled cardiac ablation generators and vascular sheaths due to labeling errors and air embolism risks, covering over 700,000 FARADRIVE units. This raises regulatory and safety concerns, potentially hurting sales and reputation in key heart-rhythm products.

    A fresh recall event that adds to negative pressure on the stock.

  • $1.5B MiRus investment with TAVR acquisition option Boston Scientific invested $1.5 billion for a 34% stake in MiRus and gained an exclusive option to buy its advanced TAVR heart-valve system for $3 billion. This expands its interventional cardiology pipeline with a less invasive option, supporting longer-term growth.

    A new strategic investment that could lift future growth prospects.

  • Nationwide recall of Orca valves Boston Scientific voluntarily recalled its Orca Single Use Air/Water and Suction Valves nationwide after a device malfunction. This adds operational and regulatory scrutiny, potentially disrupting hospital procedures and weighing on near-term sales.

    A new recall event that contributes to the negative news flow.

▼2▲1

BSX swings on recalls, restructuring, and mixed Q2 guidance

  • Sterile-packaging recalls raise quality and regulatory risk Boston Scientific recalled tens of thousands of CRE endoscopy devices worldwide due to sterile packaging breaches. This adds regulatory and quality-control concerns, potentially pressuring margins and brand trust in the endoscopy segment, and may reinforce worries about integration risk as the company scales.

    New recall event that introduces regulatory and quality risk, directly affecting BSX's outlook.

  • FDA warns on ENROUTE catheters after tip separation reports The FDA advised avoiding certain lots of Boston Scientific's ENROUTE catheters after reports of tip separation, including one serious injury. This raises safety and regulatory concerns, potentially leading to product liability, sales impact, and reputational damage in the neurovascular space.

    New FDA warning that adds regulatory and safety risk, directly affecting BSX's product sales and reputation.

  • Restructuring plan aims to cut $500M in annual costs Boston Scientific announced a global restructuring with job cuts, expecting $700–800 million in costs but $500 million in annual pre-tax savings by 2029. This should boost profitability and fund growth areas like FARAPULSE and WATCHMAN, though it signals pressure in some segments.

    New restructuring initiative that directly impacts future profitability and resource allocation.

  • Q2 beat but 2026 guidance trimmed, then stock rebounds Boston Scientific beat Q2 earnings and revenue estimates, but trimmed full-year EPS and sales growth guidance, initially sending shares down 5%. The next day, shares rose 7.1% as investors focused on the beat and raised sales outlook, though guidance remains below consensus.

    New quarterly results and guidance change that directly drive stock movement and investor sentiment.